临床2期对照替米沙坦氢氯噻嗪安慰剂.pdf

Original article 1033 Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo a b c d Athanasios J. Manolis , John L. Reid , Dick de Zeeuw , Michael B. Murphy , e ¨ ¨ f Elke Seewaldt-Becker and Jurgen Koster on behalf of the ARAMIS Study Group Objective To identify telmisartan doses that are more in 46.6% (telmisartan 20 mg), 51.7% (telmisartan 40 mg), effective than placebo and non-inferior to 53.9% (telmisartan 80 mg), 27.4% (placebo) and 42.7% hydrochlorothiazide (HCTZ) 12.5 mg, and are well (HCTZ 12.5 mg); the response rate was significantly higher tolerated, in lowering systolic blood pressure (SBP) in for telmisartan 80 mg than for HCTZ 12.5 mg (P 0.03). All- patients with isolated systolic hypertension (ISH). causality adverse events occurred in 19.9, 17.6 and 20.3% receiving telmisartan 20, 40 and 80 mg, respectively; 20.9% Patients and methods A 2–4-week single-blind placebo receiving placebo and 22.0% receiving HCTZ 12.5 mg. No run-in was followed by randomization of 1039 patients drug-related serious adverse events occurred. (age 36–84 years) with ISH [seated SBP 150–179 mmHg and seated diastolic blood pressure (DBP) 90 mmHg] to Conclusions All doses of telmisartan (20–80 mg) were once-daily double-blind tr